Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
LEQEMBI (Eisai / Biogen)
(https://leqembi.com) 📸 Data Snapshot: May 30, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Early Alzheimer’s disease treatment | LEQEMBI® (lecanemab-irmb) (https://leqembi.com)
Early Alzheimer’s disease treatment | LEQEMBI® (lecanemab-irmb)
Explore Leqembi® (lecanemab-irmb). Please see full PI, including Boxed WARNING.
NAV_HEADER_HEADING_REPEATED LEQEMBI® (lecanemab-irmb) Maintenance Treatment Options (https://leqembi.com/en/leqembi-after-18-months/)
LEQEMBI® (lecanemab-irmb) Maintenance Treatment Options
Learn more about your maintenance dosing and treatment options after receiving LEQEMBI infusions for 18 months. Please see full PI, including Boxed WARNING.
NAV_HEADER_HEADING_REPEATED_BODY LEQEMBI study results | LEQEMBI® (lecanemab-irmb) (https://leqembi.com/en/leqembi-study-results/)
LEQEMBI study results | LEQEMBI® (lecanemab-irmb)
Learn about how LEQEMBI® helps people with early Alzheimer’s disease. Please see full PI, including Boxed WARNING.
NAV_HEADER_HEADING_REPEATED_BODY Patient Stories | LEQEMBI® (lecanemab-irmb) (https://leqembi.com/en/hear-patient-stories/)
Patient Stories | LEQEMBI® (lecanemab-irmb)
Learn about Leqembi® patient stories and their care partners. Please see full PI, including Boxed WARNING.
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://leqembi.com) Early Alzheimer’s disease treatment | LEQEMBI® (lecanemab-irmb)
[H2] If you have mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, [H1] You Still Can Be [H3] With Leqembi® People shown were compensated for their time, and information is accurate as of August 2025. PAUSE PLAY Learn how LEQEMBI works See how only LEQEMBI works in 2 ways Start your conversation Get questions for your healthcare provider Connect with a specialist Act early and make an appointment KAMALA and her daughter, Jessica [IMG: Kamala outside with her family] [IMG: Kamala outside with her family] [H2] Learn about continuing LEQEMBI Only LEQEMBI has FDA-approved maintenance dosing options to keep slowing progression.* Discover more *After receiving LEQEMBI for 18 months, people have the option of starting maintenance treatment. [H2] Hear from real LEQEMBI patients and their care partners Get inspired by the real experiences of LEQEMBI patients living with early Alzheimer’s disease. [IMG: Scott and his wife, Kris] SCOTT and his wife, Kris SCOTT and his wife, Kris I am doing my best to live my life to the fullest and adjust as necessary. –SCOTT [IMG: Nina smiling] NINA NINA I enjoy going to my infusions. The people there are very nice to me. –NINA LANCE and his wife, Liz LANCE and his wife, Liz I know that LEQEMBI was the right decision for me. –LANCE [IMG: Bob walking his dog] BOB and his dog, Pooch BOB and his dog, Pooch I need to take care of me, because I want to be with my family. –BOB [IMG: Leonard and his partner, Mark, in the mountains] LEONARD and his partner, Mark LEONARD and his partner, Mark I’ll share laughs and fun with others. I wasn’t going to let Alzheimer’s get in the way of that. –LEONARD See more stories [H2] Quotes reflect the experiences of the patients featured, and each individual's experience with LEQEMBI may be different. Information is accurate as of August 2025. They were compensated for their time.
SUB-PAGE (https://leqembi.com/en/leqembi-after-18-months/) LEQEMBI® (lecanemab-irmb) Maintenance Treatment Options
[H1] LEQEMBI after 18 Months [H2] Only LEQEMBI has FDA-approved maintenance dosing options to keep slowing progression After receiving LEQEMBI infusions for 18 months, you may have the option of starting maintenance treatment. This means either switching to once-weekly (once every 7 days), at-home injections or receiving less frequent, once-monthly (once every 4 weeks) infusions. Alternatively, you may continue on your current twice-monthly (once every 2 weeks) infusion schedule if you and your healthcare provider determine that's the best plan for you. Switching to LEQEMBI injections Continuing on LEQEMBI infusions [H2] Once-weekly at-home maintenance injections with LEQEMBI IQLIK™ LEQEMBI IQLIK (pronounced “i-click” ) is a single-dose, pen-like autoinjector that you or a care partner will use to inject LEQEMBI under your skin (a subcutaneous injection). For step-by-step instructions on how to inject, see the Instructions for Use. [IMG: LEQEMBI® IQLIK™ single dose autoinjector] Takes less time to complete than infusions Can be given in the comfort and privacy of your own home You can travel and still stay on schedule* *Once the autoinjector has come to room temperature (77 ºF/25 ºC), it should be maintained at that temperature. It cannot go back into the refrigerator. [IMG: What to expect with LEQEMBI® IQLIK™ brochure] [H3] What to know before starting LEQEMBI IQLIK This guide may answer your questions about LEQEMBI IQLIK and help you get comfortable with at-home injections. Download brochure [IMG: Once a month (every 4 weeks) icon] [H2] Once-monthly maintenance infusions with LEQEMBI If you and your healthcare provider decide that you should continue receiving LEQEMBI infusions, this option will be familiar to you. All that changes is how often you receive your infusions. [IMG: LEQEMBI® infusion appointment tracker document] [H3] Keep track of your infusions Download this tracker to help you record your infusions. Download tracker NEXT: STARTING AT-HOME MAINTENANCE INJECTIONS
SUB-PAGE (https://leqembi.com/en/leqembi-study-results/) LEQEMBI study results | LEQEMBI® (lecanemab-irmb)
[IMG: Nina and her friend, smiling at each other] [IMG: Nina and her friend, smiling at each other] NINA REAL LEQEMBI PATIENT Information is accurate as of August 2025. Individuals were compensated. Quotes reflect personal experiences, which may vary. [H1] LEQEMBI STUDY RESULTS Discover how LEQEMBI helped people with early Alzheimer's disease. [H2] LEQEMBI was proven to significantly slow progression In an 18-month study of people with early Alzheimer’s disease, LEQEMBI was proven to significantly slow the progression of early Alzheimer's disease. Even though you cannot stop Alzheimer’s disease from getting worse, you can take steps to slow how fast it progresses. Early treatment with LEQEMBI can help you keep playing the roles you have for longer. How progression was measured A tool called the Clinical Dementia Rating (CDR) scale measured progression by asking people how Alzheimer’s disease impacted different abilities listed below. LEQEMBI was not proven to individually impact each of these abilities. [IMG: Light bulb icon] Remembering [IMG: Activities to do icon] Staying active [IMG: Signpost icon] Knowing your way around [IMG: Task list icon] Completing daily tasks [IMG: Purple puzzle icon] Problem-solving [IMG: Figure with purple flag hanging above them icon] Doing activities independently [H2] Who was included in the study? [IMG: Group of people icon] 1,795 people* [IMG: Age 50 and age 90 icon] Ages 50 to 90 [IMG: Diverse world icon] From different ethnic and racial backgrounds [IMG: Brain icon] With mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease *The study was divided into 2 groups. One group took LEQEMBI (898 people), and the other group did not take LEQEMBI (897 people). [IMG: A video of Nina and her daughter, Megan, spending time outdoors and smiling] [IMG: A video of Nina and her daughter, Megan, spending time outdoors and smiling] [IMG: Quotation mark icon] "I think having HOPE AND BEING POSITIVE IS EVERYTHING." [IMG: Quotation mark icon] Get to know Nina, a real LEQEMBI patient, and hear how her positive outlook led to a LEQEMBI discussion with her neurologist. [IMG: Play Video] NEXT: POTENTIAL SIDE EFFECTS
SUB-PAGE (https://leqembi.com/en/hear-patient-stories/) Patient Stories | LEQEMBI® (lecanemab-irmb)
[IMG: Bob sitting down, reading a book with his grandson] [IMG: Bob sitting down, reading a book with his grandson] BOB REAL LEQEMBI PATIENT, AND HIS GRANDSON BOB'S LEQEMBI STORY: Living with mild Alzheimer's dementia and still devoted to his family People shown were compensated for their time, and information is accurate as of August 2025. [H1] Patient stories Get inspired by real patients and their care partners who are still embracing every moment while living with early Alzheimer’s disease. [IMG: Nina and her granddaughter, outdoors and smiling] [IMG: Nina and her granddaughter, outdoors and smiling] NINA’S LEQEMBI STORY: Living with mild cognitive impairment (MCI) and still finding positivity [IMG: Bob and his wife, Cynthia, outdoors holding hands and smiling] [IMG: Bob and his wife, Cynthia, outdoors holding hands and smiling] BOB’S LEQEMBI STORY: Living with mild Alzheimer’s dementia and still devoted to his family [H2] Get inspired by the LEQEMBI community Tap to explore their thoughts. [IMG: Anthony and his wife, Karen] ANTHONY and Karen [IMG: Anthony and his wife, Karen] “Without my family and friends, I would not feel as strong as I do.” — Anthony [IMG: Lance sitting down, reading] LANCE [IMG: Lance sitting down, reading] “I know that LEQEMBI was the right decision for me.” — LANCE [IMG: Bob walking his dog] BOB [IMG: Bob walking his dog] “I need to take care of me, because I want to be with my family.” — Bob [IMG: Scott and his wife, Kris] SCOTT and Kris [IMG: Scott and his wife, Kris] “I am doing my best to live my life to the fullest and adjust as necessary.” — Scott [IMG: Nina smiling] NINA [IMG: Nina smiling] “I enjoy going to my infusions. The people there are very nice to me.” — NINA [IMG: Chris and his wife, Janet] CHRIS and Janet [IMG: Chris and his wife, Janet] “LEQEMBI infusions give me hope.” — CHRIS [IMG: Leonard and his partner, Mark] LEONARD and Mark [IMG: Leonard and his partner, Mark] “I like sharing laughs and fun with others. I wasn’t going to let Alzheimer’s get in the way of that.” — Leonard [IMG: Kamala and her grandson, at a playground] KAMALA [IMG: Kamala and her grandson, at a playground] “I want to continue being a vital part of my community and family; that keeps me motivated to continue treatment.” — KAMALA [IMG: Doyle and his wife, Starr] DOYLE and Starr [IMG: Doyle and his wife, Starr] “We both feel lucky he is on LEQEMBI.” — DOYLE AND STARR [IMG: Rachel and her husband, Doug] RACHEL and Doug [IMG: Rachel and her husband, Doug] “LEQEMBI seemed like a way that I could still be me.” — Rachel TAP TO VIEW MORE [H2] Real LEQEMBI patients and their family. Quotes reflect the experiences of the patients featured, and each individual's experience with LEQEMBI may be different. Information is accurate as of August 2025. They were compensated for their time. Only a healthcare provider can diagnose early Alzheimer's disease and help find the right treatment option. [IMG: Checklist icon] Create a simple discussion guide for your next appointment. Start my guide START MY GUIDE NEXT: FREQUENTLY ASKED QUESTIONS
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 1 | 1 |
| /en/leqembi-after-18-months/ | 1 | 1 |
| /en/leqembi-study-results/ | 2 | 1 |
| /en/hear-patient-stories/ | 15 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: LEQEMBI (Eisai / Biogen) (leqembi.com)
A professionally executed pharmaceutical landing site that provides high-quality clinical study parameters but cloaks them in expensive emotional marketing. While the substance is present, the reliance on compensated testimonials and the total lack of modern structured data (Schema) prevents it from achieving a minimal BS score.
Implement Organization and MedicalStudy schema to provide a verifiable digital footprint for the clinical data. Replace the repetitive ‘Time’s Best Inventions’ heading with direct links to the peer-reviewed study results in the New England Journal of Medicine or similar journals. Reduce the reliance on compensated patient testimonials by including real-world evidence (RWE) or post-market surveillance data as it becomes available. Add a specific section naming the scientific leads or medical directors with links to their professional credentials to close the expert authority gap.
The site perfectly matches the Pharma and Biotech industry, focusing on a specific FDA-approved therapeutic (lecanemab-irmb) for Alzheimer’s disease. It adheres to regulatory requirements including the prominent Boxed Warning and Important Safety Information (ISI).
“The score is primarily driven by Information Density (power words vs specific nouns) and Identity/Authority (lack of schema). The site's near-perfect Semantic Coherence score reflects a very disciplined marketing strategy that avoids contradictory claims, which is typical of highly regulated medical products.”
This training module utilizes a snapshot of public data from LEQEMBI (Eisai / Biogen), captured on May 30, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to LEQEMBI (Eisai / Biogen): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://leqembi.com to view the most current version of its content and learn from the source what this company is about and what it offers.